secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-133766
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q1 net loss $40.1M, VOWST sales $10.1M; SER-155 data expected Q3
----------------------------------------------------------------------

- Net loss $40.1M vs $71.2M YoY; VOWST net sales $10.1M (642 units).
- Received ~1,411 VOWST enrollment forms, ~1,083 new patient starts in Q1.
- SER-155 Phase 1b Cohort 2 data readout expected end of Q3 2024.
- Cash $111.2M; expects runway into Q4 2024; may draw $45M debt tranche or use ATM.
- Marella Thorell appointed EVP and CFO following David Arkowitz's retirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524133766/0001193125-24-133766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524133766/d812139d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-133766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer